The role of hyperuricemia in vascular disorders

Current Opinion in Rheumatology

Volumn 21, Issue 2, 2009, Pages 132-137

  Edwards, N Lawrence ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Asymptomatic hyperuricemia; Chronic kidney disease; Coronary artery disease; Hypertension; Pro oxidant

Indexed keywords

URIC ACID;

CHRONIC KIDNEY DISEASE; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENDOTHELIUM LESION; GOUT; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY FAILURE; METABOLIC SYNDROME X; NEPHROLITHIASIS; OBESITY; PRIORITY JOURNAL; REVIEW; STROKE; VASCULAR DISEASE;

ANIMALS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; EVOLUTION; HUMANS; HYPERTENSION; HYPERURICEMIA; KIDNEY FAILURE, CHRONIC; METABOLIC SYNDROME X; RISK FACTORS; URIC ACID; VASCULAR DISEASES;

EID: 62349096572     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283257b96     Document Type: Review

References (59)

1. Feig DI, Kang D-H, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359:1811-1821. Excellent review of the scientific studies supporting and refuting the role of uric acid in cardiovascular disease.
2. Mohamed FA. On chronic Bright's disease, and its essential symptoms. Lancet 1879; 1:399-401.
3. Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med 2008; 75:S13-S16.
4. Wu X, Muzny DM, Lee CC, Caskey CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 1992; 34:78-84.
5. Johnson RJ, Gaucher EA, Sautin YY, et al. The planetary biology of ascorbate and uric acid and their relationship with the epidemic of obesity and cardiovascular disease. Med Hypotheses 2008; 71:22-31. Recent review of uric acid's role as an antioxidant and pro-oxidant in human health and disease. It also reviews the evolutionary theories linking the loss of endogenous vitamin C production and the development of hyperuricemia.
6. Orowan E. The origin of man. Nature 1955; 175:683-684.
7. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981; 78:6858-6862.
8. Simie MG, Jovanovic SV. Antioxidation mechanisms of uric acid. J Am Chem Soc 1989; 111:5778-5782.
9. Squadrito GL, Cueto R, Splenser AE, et al. Reaction of uric acid with peroxynitrate and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys 2000; 376:333-337.
10. Hink HU, Santanam N, Dikalov S, et al. Peroxidase properties of extracellular superoxide dismutase: role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol 2002; 22:1402-1408.
11. Watanabe S, Kang DH, Feng L, et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002; 40:355-360.
12. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of myocardial infarction. Arthritis Rheum 2006; 54:2688-2696.
13. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987; 82:421-426.
14. Rich RW. Uric acid: is it a risk factor for cardiovascular disease? Am J Cardiol 2000; 85:1018-1021.
15. Rathman W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Ann Epidemiol 1998; 8:250-261.
16. Leyva F, Anker S, Swan JW, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997; 8:858-865.
17. Brand FN, McGee DL, Kannell WB, et al. Hyperuricemia as a risk factor of coronary heart disease: the Framingham study. Am J Epidemiol 1985; 121:11-18.
18. Moriarity JT, Folsom AR, Iribarren C, et al. Serum uric acid and risk of coronary heart disease: atherosclerosis risk in communities (ARIC) study. Ann Epidemiol 2000; 10:136-143.
19. Wannamethee SG, Shaper AG, Whincup PH. Serum urate and the risk of major coronary heart disease events. Heart 1997; 78:147-153.
20. Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004; 44:642-650.
21. Tomita M, Mizuno S, Yamanaka H, et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol 2000; 10:403-409.
22. Staessen J. The determinants and prognostic significance of serum uric acid in elderly patients of the European Working Party on High Blood Pressure in the Elderly trial. Am J Med 1991; 90:503-538.
23. De Leeuw PW, Thijs L, Birkenhager WH, et al. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol 2002; 13:2213-2222.
24. Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol 2007; 18:287-292. This subset analysis of the Health Professionals Follow-up Study demonstrated that when adjustments were made for known hypertension risk factors, as well as for fasting insulin and serum lipids, there was no independent association between serum urate levels and the risk of incident hypertension in older men.
25. Talbott JH, Terplan KL. The kidney and gout. Med 1960; 39:405-465.
26. Klininberg JR, Kippen I, Bluestone R. Hyperuricemic nephropathy: pathologic features and factors influencing urate deposition. Nephron 1975; 14:88-98.
27. Beck L. Requiem for gouty nephropathy. Kidney Int 1986; 30:280-287.
28. Eng E, Veniant M, Floege J, et al. Renal proliferation and phoentypic changes in rats with two-kidney, one clip Goldblatt hypertension. Am J Hypertens 1994; 7:177-185.
29. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38:1101-1106.
30. Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. Nature 2002; 417:447-452.
31. Price KL, Sautin YY, Long DA, et al. Human vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol 2006; 17:1791-1795.
32. Alper AB Jr, Chen W, Yau L, et al. Childhood uric acid predicts adult blood pressure: the Bogalusa Heart study. Hypertension 2005; 45:34-38.
33. Dyer AR, Liu K, Walsh M, et al. Ten-year incidence of elevated blood pressure and its predictors: the CARDIA study. J Hum Hypertens 1999; 13:13-21.
34. Jossa F, Farinaro E, Panico S, et al. Serum uric acid and hypertension: the Olivetti Heart study. J Hum Hypertens 1994; 8:677-681.
35. Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007; 49:298-303. This study uses a subset of men from the MRFIT database who did not have hypertension or the metabolic syndrome at baseline to demonstrate that hyperuricemia increases the risk of developing hypertension by 80% and is independent of other confounders.
36. Masuo K, Kawaguchi H, Mikami H. Serum uric acid and plasma norep inephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003; 42:474-480.
37. Mellen PB, Bleyer AJ, Erlinger, et al. Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension 2006; 48:1037-1042.
38. Nagahama K, Inoue T, Iseki K, et al. Hyperurioemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res 2004; 27:835-841.
39. Nakanishi N, Okamoto M, Yoshida H, et al. Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers. Eur J Epidemiol 2003; 18: 523-530.
40. Taniguchi Y, Hayashi T, Tsumura K, et al. Serum uric acid and the risk for hypertension and type 2 diabetes in Japanese men: the Osaka Health Survey. J Hypertens 2001; 19:1209-1215.
41. Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008; 67:960-966. This study examined the medical records of nearly 5 million patients in the UK and Germany and showed that patients with gout had a high frequency of comorbidities. The frequency of the comorbidities varied between the two countries with obesity being the highest in the UK and diabetes in Germany.
42. Dehghan A, van Hoek M, Sijbrands EJ, et al. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 2008; 31:361-362. Using the database from the large Rotterdam Study, this study describes serum urate a strong, independent risk for the development of type 2 diabetes.
43. Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2006; 290:F625-F631.
44. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971-1992. JAMA 2000; 283:2404-2410.
45. Liese AD, Hense H-W, Lowel H, et al. Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg Cohort. Epidemiology 1999; 10:391-397.
46. Verdecchia P, Schillaci G, Reboldi GP, et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension: the PIUMA Study. Hypertension 2000; 36:1072-1078.
47. Franse LV, Pahor M, Di Bari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program. J Hypertens 2000; 18:1149-1154.
48. Wang J-G, Staessen JA, Fagard RH, et al. Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension 2001; 37:1069-1074.
49. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension. JAMA 2008; 300:924-932. This short-term, crossover study demonstrates that allopurinol reduces blood pressure in adolescents with essential hypertension. This supports the hypothesized role of uric acid in the development of hypertension and vascular comorbidities.
50. Kinsey D, Walther R, Sise HS, et al. Incidence of hyperuricemia in 400 hypertensive patients. Circulation 1961; 24:972-976.
51. Kahn HA, Medalie JH, Neufeld HN, et al. The incidence of hypertension and associated factors: the Israel ischemic heart disease study. Am Heart J 1972; 84:171-182.
52. Klein R, Klein BE, Cornoni JC, et al. Serum uric acid. Its relationships to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch Int Med 1973; 132:401-410.
53. Perlstein TS, Gumieniak O, Williams GH, et al. Uric acid and the development of hypertension in the Normative Aging Study. Hypertension 2006; 48:1031-1036.
54. Sin Y, Leung K, Tong M, Kwan T. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47:51-59.
55. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998; 57:545-549.
56. Gibson T, Rodgers V, Potter C, Simmonds HA. Allopurinol treatment and its effect on renal function in gout: a controlled study. Ann Rheum Dis 1982; 41:59-65.
57. Ward H. Uric acid as an independent risk factor in the treatment of hypertension. Lancet 1998; 352:670-671.
58. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007; 120:442-447. The direct relationship between hyperuricemia and the individual components of the metabolic syndrome has been reported. This large study using the NHANES III database is the first to show that the prevalence of the metabolic syndrome itself increases substantially with rising serum urate levels.
59. Hwang IS, Ho H, Hoffman RB, Reaves GM. Fructose-induced insulin resistance and hypertension in rats. Hypertension 1987; 10:512-516.